aibioAcadia awaits Federal Circuit ruling in Nuplazid patent suits; Zydus trial set for Nov. 2
Tickers ACAD
Acadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026.
Key facts
- Company
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
- News type
- Legal
- Primary source
- Acadia Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is the plaintiff in a series of patent infringement suits against generic drug makers, according to its 10-Q filed August 5, 2026. The cases, in the U.S. District Court for the District of Delaware, concern Orange Book-listed patents covering Nuplazid (pimavanserin). Acadia filed the first complaints on July 24 and July 30, 2020. The 10-Q gives no Delaware case numbers.
Two matters are still active. A final judgment for Acadia entered June 9, 2025 in the second set of cases is on appeal at the Federal Circuit, and a separate case filed February 14, 2025 against Zydus is set for trial starting November 2, 2026. Across the cases the 10-Q names as defendants Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited, Zydus Lifesciences Limited and Zydus Worldwide DMCC.
The case
The first complaints, called the Pimavanserin I Cases, allege infringement of Orange Book-listed patents covering Nuplazid. On October 21, 2022 Acadia filed additional complaints against Aurobindo, MSN and Zydus over another listed patent (the Pimavanserin II Cases).
The 2025 complaint targets Zydus' proposed 34 mg pimavanserin tablet. On September 9, 2025 Acadia filed a First Amended Complaint alleging that Zydus breached the March 31, 2023 settlement agreement.
Defendants
The 10-Q names these defendants: Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.; Hetero Labs Limited, Hetero Labs Limited Unit-V and Hetero USA Inc.; MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.; and Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited. In the 2025 case the defendants are Zydus Lifesciences Limited, Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc.
Hetero settled effective April 22, 2021 and the case was dismissed May 3, 2021. Under that agreement Hetero may launch its generic product on February 27, 2038, subject to triggers for earlier launch. Zydus settled the first two sets of cases effective March 31, 2023, with launch dates of September 23, 2036 for 10 mg tablets and February 27, 2038 for 34 mg capsules, also subject to earlier-launch triggers. The Zydus case was dismissed April 5, 2023. Claims against Teva are stayed, and Teva is bound by the result against the remaining defendants, Aurobindo and MSN.
Where it stands
In the first set of cases, the district court entered final judgment for Acadia on January 11, 2024. It found that MSN's submission of ANDA No. 214925 was an act of infringement and that the '740 patent was not invalid. The Federal Circuit affirmed on June 9, 2025.
In the second set, a bench trial ran December 3 to December 6, 2024, and post-trial briefing ended February 12, 2025. On June 9, 2025 the court issued final judgment for Acadia that Aurobindo's ANDA infringes the asserted Nuplazid patent and that the defendants did not show the patent invalid. MSN and Aurobindo appealed on June 16, 2025. Briefing finished December 19, 2025, and no oral argument has been scheduled.
Acadia says it cannot predict the outcome of its legal matters or estimate possible losses from them.
Why it matters to shareholders
Nuplazid net product sales were $183.2 million in the quarter ended June 30, 2026, against $168.5 million a year earlier, according to the 10-Q. Acadia also markets Daybue.
A 10-Q risk factor says that if Acadia's patents are successfully challenged, it may face generic competition before its U.S. Orange Book listed patents expire. It adds that suits to enforce them are expensive and time consuming. The 10-Q describes no further settlement terms or generic launch dates for MSN or Aurobindo.